Janus Henderson Group PLC Morphic Holding, Inc. Transaction History

Janus Henderson Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$26.12 - $34.07 $5,015 - $6,541	-192 Reduced 1.47%	12,832 $437,000
Q4 2023 Feb 14, 2024	SELL	$19.95 - $31.0 $438 - $682	-22 Reduced 0.17%	13,024 $376,000
Q3 2023 Nov 14, 2023	SELL	$21.33 - $59.42 $3.04 Million - $8.47 Million	-142,571 Reduced 91.62%	13,046 $298,000
Q2 2023 Aug 14, 2023	SELL	$34.33 - $62.11 $1.55 Million - $2.8 Million	-45,019 Reduced 22.44%	155,617 $8.92 Million
Q1 2023 May 15, 2023	BUY	$26.01 - $48.69 $5.22 Million - $9.77 Million	200,636 New	200,636 $7.55 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.